{"disease":{"id":"acute-myeloid-leukemia-in-relapse","name":"acute myeloid leukemia in relapse"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05124288","title":"Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Ciceri Fabio","has_results":false},{"nct_id":"NCT02134782","title":"Yoga Fatigue Study","phase":"NA","overall_status":"TERMINATED","enrollment_count":125,"lead_sponsor_name":"The Hospital for Sick Children","has_results":false},{"nct_id":"NCT06372717","title":"A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Apollo Therapeutics Ltd","has_results":false},{"nct_id":"NCT03053206","title":"A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":84,"lead_sponsor_name":"All India Institute of Medical Sciences","has_results":false},{"nct_id":"NCT05587088","title":"Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":82,"lead_sponsor_name":"Hospital Universitario San Ignacio","has_results":false},{"nct_id":"NCT03690154","title":"A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","has_results":false},{"nct_id":"NCT03755154","title":"Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":60,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT04402541","title":"Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Cleave Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04541277","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":55,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT05546580","title":"Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Oryzon Genomics S.A.","has_results":false},{"nct_id":"NCT06906380","title":"A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":49,"lead_sponsor_name":"ARCE Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02768792","title":"High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT04191187","title":"Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT03957915","title":"Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Institut Paoli-Calmettes","has_results":false},{"nct_id":"NCT02159495","title":"Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":31,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04678401","title":"IS-free Treg HaploHCT","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05292664","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Andrew E. Place, MD","has_results":false},{"nct_id":"NCT01550224","title":"Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Steven E. Coutre","has_results":true},{"nct_id":"NCT03766126","title":"Lentivirally Redirected CD123 Autologous T Cells in AML","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT03674411","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT05488132","title":"Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Xuzhou Medical University","has_results":false},{"nct_id":"NCT06125652","title":"Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Xuzhou Medical University","has_results":false},{"nct_id":"NCT05066958","title":"Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT05105152","title":"PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Seattle Children's Hospital","has_results":false},{"nct_id":"NCT05597306","title":"Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Terrence J Bradley, MD","has_results":false},{"nct_id":"NCT07087847","title":"Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04914845","title":"KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"University of Colorado, Denver","has_results":true},{"nct_id":"NCT06017258","title":"A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT04716452","title":"Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Keystone Nano, Inc","has_results":false},{"nct_id":"NCT04678336","title":"CD123 Redirected T Cells for AML in Pediatric Subjects","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT06128044","title":"CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Caribou Biosciences, Inc.","has_results":false},{"nct_id":"NCT06201247","title":"Off-the-shelf CD123 CAR-NK for R/R AML","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04321161","title":"Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"University of Freiburg","has_results":false},{"nct_id":"NCT02438761","title":"PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Institut Curie","has_results":false}],"total":35},"guidelines":[],"source":"Drug Landscape verified database"}